No Data
No Data
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright analyst Robert Burns maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 24.0
ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment
ArriVent BioPharma (AVBP) said Wednesday that it signed a collaboration agreement with Alphamab Oncology's Jiangsu Alphamab Biopharmaceuticals unit to discover, develop, and commercialize antibody dru
Express News | ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
Express News | Arrivent Announces a Multi-Target ADC Collaboration With Alphamab
Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products
Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements
No Data